Table 2.
Trial outcomes of Studies Included in the Meta-Analysis
| First authors, year | Headache days per 28-day period (d), mean ± SD | PedMIDAS score, mean ± SD | ≥ 50% Relative reduction in headache frequency,n(%) | |||
|---|---|---|---|---|---|---|
| Topiramate | Placebo | Topiramate | Placebo | Topiramate | Placebo | |
| Paul Winner,2005 | 3.1 ± 3 | 2.4 ± 2.8 | NA | NA | 59(54.63) | 23(46.94) |
| C. V. S. Lakshmi,2007 | 4.27 ± 1.95 | 7.48 ± 5.94 | 10.2 ± 6.39 | 23.7 ± 11.9 | 20(95.24) | 11(55) |
| Donald Lewis,2009 | 2.4 ± 3.11 | 3.5 ± 3.47 | NA | NA | 45(64.29) | 15(45.45) |
| Scott W.Powers,2017 | 4.6 ± 5.3 | 5.2 ± 6.5 | 14.4 ± 17.3 | 19.4 ± 20.8 | 72(55.38) | 20(60.61) |
SD standard deviations, NA not available